Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger's Q2 2026 net income turned positive, supported by a $48.9M gain from the Ajax sale, while cash reserves increased to $418.8M. The company has cut its pipeline and shifted away from independently developing clinical assets, strengthening its balance sheet but underscoring strategic retrenchment. Software growth deceleration and pipeline setbacks remain key headwinds.

Analysis

The key valuation change is not the reported profitability but the reduction in cash-burn and binary clinical-risk exposure. SDGR should increasingly be valued as a computational drug-discovery software platform plus a de-risked royalty/equity portfolio, rather than as a capital-intensive biotech developer; that can support multiple stabilization if recurring software growth re-accelerates. However, a one-time asset gain does not establish durable earnings power, so investors should focus on annual contract value, net retention, large-pharma seat expansion, and R&D expense discipline rather than GAAP net income.

Near term, the strategic reset removes a major overhang: fewer internally funded programs lowers required capital and extends the runway, reducing the probability of a dilutive equity raise over the next 12-18 months. The trade-off is that SDGR has ceded some upside from wholly owned clinical assets and becomes more dependent on partners executing; milestones and royalties are longer-duration, lower-visibility cash flows. Competitively, a weaker standalone therapeutic ambition could improve the company's credibility with pharma customers that may have viewed it as a potential downstream competitor, benefiting software bookings over the next 1-3 quarters.

Consensus may underappreciate the possibility that AI-drug-discovery enthusiasm alone will not re-rate SDGR: buyers will demand evidence that computational workflows are converting into contracted software revenue, not merely scientific adoption. A sustained software-growth miss or renewed operating-expense expansion would likely compress the stock back toward cash-adjusted platform value. Conversely, two consecutive quarters of accelerating recurring revenue and stable retention would validate a higher-margin software narrative and could drive a meaningful re-rating over 6-12 months.

Key Decisions for Investors

• Maintain SDGR as a watch-to-long rather than chase the accounting-driven earnings improvement; initiate only after the next earnings release confirms recurring software revenue acceleration and management holds operating-expense guidance. Target a 6-12 month holding period, with thesis invalidated by another material deceleration in software growth or an increase in cash burn.
• For existing SDGR exposure, separate valuation of net cash and strategic investments from the core software business; avoid underwriting the asset-sale gain as recurring earnings. Reduce if the stock re-rates materially before evidence of improved net retention or new enterprise-pharma contract wins.
• Use a relative-value framework: long SDGR versus a basket of early-stage, cash-burning AI-biotech developers only if SDGR's forward cash runway remains superior and software metrics improve. The pair is designed to capture de-risking while limiting broad AI-biotech sentiment risk; close if partner-driven milestone economics fail to replace reduced internal-pipeline optionality.
• Do not treat AJAX as a standalone liquid public-market trade without confirming its listing status, consideration structure, and any continuing SDGR economic interest. Monitor disclosed milestone, royalty, or equity-retention terms, as these determine whether the transaction creates recurring upside or was primarily a balance-sheet event.